摘要
目的讨论左西孟旦和盐酸多巴酚丁胺治疗急性心衰的效果及对BNP水平的影响对比。方法选取2017年2月~2018年3月我院收治的100例急性心衰患者作为研究对象,按照随机数字表法将其分为两组。对照组50例患者予盐酸多巴酚丁胺治疗,观察组50例患者予左西孟旦治疗。两组患者均予常规检查及标准药物治疗。治疗7 d后,比较两组患者的临床治疗效果;比较两组患者左心室收缩末期容量(LVESV)、左心室舒张末期容积(LVEDV)、左室射血分数(LVEF)、每搏量(SV)的改善情况;比较两组患者脑尿钠肽(BNP)、炎性分子指标[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]的变化情况;比较两组患者的不良反应发生情况。结果治疗后,观察组患者的临床治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者的LVESV、LVEDV低于治疗前,LVEF高于治疗前,观察组患者的SV高于治疗前,差异有统计学意义(P<0.05)。且观察组患者治疗后的LVESV低于对照组,LVEF、SV高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者的BNP、IL-6、TNF-α、hs-CRP水平均低于治疗前,差异有统计学意义(P<0.05)。且观察组患者治疗后的BNP、IL-6、TNF-α、hs-CRP水平均低于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论左西孟旦治疗急性心衰的临床效果优于盐酸多巴酚丁胺,可降低患者的BNP水平,具有可靠性。
Objective To discuss the effect of Levosimendan and Dobutamine Hydrochloride on the treatment of acute heart failure and its effect on the level of BNP. Methods A total of 100 patients with acute heart failure who were ad- mitted to our hospital fi＇om February 2017 to March 2018 were selected as study objects and divided into two groups according to the random number table method. And 50 patients in the control group were treated with Dobutamine Hy- drochloride, and 50 patients in the observation group were treated with Leosimendan. Routine examination and standard medication were administered to both groups. After 7 days of treatment, the clinical effects of the two groups were compared. The improvement of the left ventricular end-systolic volume （LVESV）, left ventricular end-diastolic volume （LVEDV）, left ventricular ejection fi＇action （LVEF） and stroke volume （SV） of the two groups were compared. The changes of brain natriuretic peptide （BNP）, inflammatory molecular indicators [interleukin-6 （IL-6）, tumor necrosis factor-α （TNF-α）, hypersensitive e-reactive protein （hs-CRP）] in the two groups were compared. Adverse reactions were compared between the two groups. Results After the treatment, the overall effective rate of clinical treatment in the ob- servation group was higher than that in the control group, the difference was statistically significant （P〈0.05）. After treatment, the LVESV and LVEDV in the two groups were lower than those before treatment, the LVEF was higher than that before treatment, and SV in the observation group was higher than that before treatment, the differences were sta- tistically significant （P〈0.05）. After treatment, the LVESV in the observation group was lower than the control group, and LVEF and SV were higher than those in the control group, the differences were statistically significant （P〈0.05）. After treatment, the levels of BNP, IL-6, TNF-α, and hs-CRP in the two groups were all lower than those before treatment, the differences were statistically significant （P〈0.05）. And the levels of BNP, IL-6, TNF-α, and hs-CRP in the obser- vation group were all lower than those in the control group, the differences were statistically significant （P〈0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups （P〉0.05）. Con- clusion The clinical effect of Leosimendan on the treatment of acute heart failure is better than that of Dobutamine Hydrochloride. And Leosimendan can reduce the level of BNP and be reliability.
作者
谭位华
卿国忠
陆煜
彭正良
TAN Wei-hua;QING Guo-zhong;LU Wei;PENG Zheng-liang(Department of Emergency,the First Affiliated Hospital of Nanhua University,Hu＇nan Province,Hengyang 421001,China)
出处
《中国当代医药》
2018年第28期48-51,共4页
China Modern Medicine
